GlassScriptPhysician profile
Kayli Eslinger
NPI 1306599485
$12,702.68
in general payments reported to CMS, 2019-2025
36 companies · $3,868 in 2025
The $3,868 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,831 · 2023: $3,546 · 2024: $3,458 · 2025: $3,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,525.19 |
| Education | $346.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,173.07 | 2022-2025 | |
| Janssen Biotech, INC. | $1,538.50 | 2022-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,497.04 | 2022-2025 | Trulance, Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $729.35 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $555.22 | 2022-2025 | Tremfya, Stelara |
| Intra-Sana Laboratories | $553.26 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Phathom Pharmaceuticals, INC. | $440.33 | 2023-2025 | Voquezna |
| Pfizer INC. | $434.27 | 2022-2025 | |
| Ardelyx, INC. | $416.16 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $407.47 | 2022-2025 | Sucraid, Sucraid |
| Vivus LLC | $301.98 | 2022-2025 | Pancreaze |
| Lilly USA, LLC | $292.58 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $253.79 | 2023-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $250.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $230.51 | 2022-2024 | Linzess |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $220.29 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $193.30 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $178.53 | 2025 | Wegovy |
| Evoke Pharma, INC. | $165.97 | 2022-2023 | Gimoti |
| Genzyme Corporation | $148.03 | 2022-2024 | |
| Regeneron Pharmaceuticals, INC. | $135.21 | 2022 | |
| Celltrion USA INC. | $90.57 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $62.95 | 2025 | Iqirvo |
| Lucid Diagnostics INC. | $56.07 | 2025 | |
| Medtronic, INC. | $52.99 | 2025 | Interstim |
| Nestle Healthcare Nutrition INC. | $47.97 | 2022-2023 | |
| Braintree Laboratories, INC. | $47.76 | 2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $41.86 | 2022-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $38.76 | 2022-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.80 | 2023-2024 | Cyltezo |
| Amgen INC. | $26.32 | 2023 | Avsola, Amjevita |
| Sandoz INC. | $24.96 | 2023 | Hyrimoz |
| Aimmune Therapeutics, INC. | $24.66 | 2024 | |
| Enterra Medical, INC. | $17.13 | 2025 | |
| Daiichi Sankyo INC. | $16.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayli Eslinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.